HTB

World AIDS 22 Amsterdam 2018

22nd International AIDS Conference (AIDS 2018) – third reports

Dolutegravir twice daily is effective and tolerable with rifampicin: 48 week results from the INSPIRING study

TAF exposures during pregnancy and postpartum appear adequate but more data are needed

High rate of unintended pregnancy among HIV positive African women on ART

22nd International AIDS Conference (AIDS 2018) – second reports

Namibia close to achieving 90-90-90 targets

Changing comorbidities in HIV positive people older than 60 at London clinic

High rates of anal HPV infection in gay men using PrEP in IPERGAY: the role of vaccination

HCV incidence and reinfection in HIV negative gay men using PrEP in the Netherlands

FDA-approved compounds that might selectively reverse HIV latency

Lack of impact on viral reservoir with α4β7 monoclonal antibody vedolizumab: macaque results not matched in humans

Janssen HIV vaccine: update from APPROACH and largescale efficacy study

Viral load testing in Latin America and the Caribbean

Access to viral load testing increased from 14% to 61% over two years in Côte d’Ivoire

Resolving a diagnosis for people with persistently indeterminate HIV test results

22nd International AIDS Conference (AIDS 2018) – first reports

Caution on press conference news from AIDS 2018

Zero HIV transmissions in PARTNER 2 study after gay couples had sex 77,000 times without condoms – an undetectable viral load stops HIV

DTG/3TC dual therapy is non-inferior to triple-ART in GEMINI study

Once-daily reduced dose darunavir/ritonavir (400 mg/100 mg) is non-inferior to twice-daily lopinavir/ritonavir in South African switch study  

WHO recommends dolutegravir widely but women’s access will depend on contraception provision

No additional neural tube defects among a further 170 preconception dolutegravir exposures in Botswana: Tsepamo study (July 2018)

Swifter viral load suppression with dolutegravir vs efavirenz in late pregnancy: results from DolPHIN 1

Using PrEP with feminising hormone therapy supports daily PrEP dosing for transwomen

Daily and on-demand PrEP both prevent HIV in Prévenir study: high adherence by gay Parisians

AIDS 2018 online: links to selected webcasts

What to watch: HIV cure-related research at AIDS 2018

AIDS 2018: Programme online and late-breaker highlights announced three weeks before the conference